Medicines Optimisation Research and Enterprise Group

Organization profile

Profile Information

Advances in our understanding of pathology and pharmacology have led to an explosion of new medicines in the past 30 years.  Large, biological molecules are now commonplace in the formularies of clinical specialities, and smaller drug compounds which act on a diverse range of targets are providing clinicians and patients with much needed options. 

Yet despite this, medicines, which are the most common therapeutic intervention, carry a risk of harm, and in some patient groups are a significant cause of iatrogenic injury.   There is also a paucity of evidence regarding using medicines simultaneously in patients with multi-morbidity (e.g. the elderly, or new-born infants) as they are not consistently included in clinical trials.  Where data is available, it is interesting to note that there is considerable variation in the therapeutic response patients show to medicines – only some of which we are beginning to understand.  Together, these factors make prescribing complex, and prone to error.

The medicines optimisation research group therefore has three clear goals to improve our understanding of how use medicines safely and effectively:

The science of medicines: Develop world-class research that utilises basic science research expertise and techniques to increase our understanding of medicines.  Areas of research expertise include: pharmacokinetics, pharmacology and microbiology; pharmaceutical formulation; clinical bioanalysis; pharmacogenetics and pharmacogenomics.

The clinical use of medicines: Develop world-class research that examines human behaviours and psychology in health and disease.  Areas of research expertise include: behavioural medicine, health psychology, and paediatrics.

Medicines related education, training and support: Identify and test new approaches to educate and assess the current and future workforce with regards to medicines optimisation, and medicines optimisation research.

Our external partners include, Brighton and Sussex University Hospitals NHS Trust and Brighton and Sussex Medical School

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Pharmacists Medicine & Life Sciences
Counterfeit Drugs Medicine & Life Sciences
Lebanon Medicine & Life Sciences
Tenofovir Medicine & Life Sciences
efavirenz Medicine & Life Sciences
Private Practice Medicine & Life Sciences
Drug-Related Side Effects and Adverse Reactions Medicine & Life Sciences
Pharmacy Education Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2017 2018

  • 13 Article
  • 2 Abstract
  • 2 Other
  • 1 Conference contribution with ISSN or ISBN

Age-related changes to the expression of nuclear factor erythroid 2-like 2 (Nrf2), a regulatory antioxidant and xenobiotic defence gene

Scutt, G., Overall, A., Bakrania, P., Krasteva, E., Parekh, N., Ali, K., Davies, G. & Rajkumar, C. 2018 14th International Congress of the European Geriatric Medicine Society: Advancing Geriatric Medicine in a Modern World. (European Geriatric Medicine)

Research output: Chapter in Book/Report/Conference proceedingConference contribution with ISSN or ISBN

Xenobiotics
Antioxidants
Comorbidity
Drug-Related Side Effects and Adverse Reactions
Messenger RNA

Association of a regulatory anti-oxidant and drug-metabolising gene with multi-morbidity and adverse drug reactions in older adults

Scutt, G., Overall, A., Bakrania, P., Krasteva, E., Parekh, N., Ali, K., Davies, G. & Rajkumar, C. 2018

Research output: Contribution to conferenceOther

Drug-Related Side Effects and Adverse Reactions
Oxidants
Comorbidity
Morbidity
Pharmaceutical Preparations
Private Practice
Physical Therapists
Referral and Consultation
Marketing
Benchmarking

Activities 2018 2018

  • 1 Invited talk

DfI: why should I?

Olivier, G. (Invited presenter), Bryant, E. (Invited presenter)
29 Apr 2018

Activity: Invited talk